Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
UCB Inc. et al v. Accord Healthcare Inc. et al
Case Number:
1:13-cv-01206
Court:
Nature of Suit:
Judge:
Firms
- Blank Rome
- Heyman Enerio
- Morris James
- Morris Nichols
- Murphy Spadaro & Landon
- Perkins Coie
- Phillips McLaughlin
- Richards Layton
- Shaw Keller
- Young Conaway
Companies
- Alembic Pharmaceuticals Ltd.
- Allergan PLC
- Amneal Pharmaceuticals Inc.
- Apotex Inc.
- Aurobindo Pharma Ltd.
- Breckenridge Pharmaceutical Inc.
- Cadila Pharmaceuticals Ltd.
- Glenmark Pharmaceuticals Ltd.
- Hetero Labs Ltd.
- Ranbaxy
- Research Corporation Technologies Inc.
- Sandoz International GmbH
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- UCB SA
- Viatris Inc.
- Zydus Pharmaceuticals Inc.
Sectors & Industries:
-
August 16, 2016
UCB's Anti-Convulsant Patent Is Valid, Delaware Judge Rules
A UCB Inc. patent for the anti-convulsant Vimpat is valid, a Delaware federal judge said in an opinion unsealed on Monday, blocking attempts by Actavis Inc., Mylan Pharmaceuticals Inc., Apotex Inc.. and several other drugmakers to make and sell a generic versison of the drug.
-
January 09, 2015
Generics Makers Lose Bid To Nix Vimpat Patent In AIA Review
The Patent Trial and Appeal Board on Friday denied a petition for inter partes review of a patent covering UCB Inc.'s epilepsy drug Vimpat, rejecting invalidity arguments by Actavis Inc. and a host of other generics makers accused of infringement.